Positive results from DREAMM-7 head-to-head Ph 3 trial for Blenrep in R/R multiple myeloma announced December 4, 2023
New Preliminary OS data in Selinexor-Treated Patients with Advanced or Recurrent TP53 WT Endometrial Cancer from the SIENDO Study Announced December 4, 2023
Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population Announced December 4, 2023
Imfinzi + Avastin met primary endpoint for PFS in liver cancer eligible for embolisation in EMERALD-1 Ph 3 trial December 4, 2023
KEYTRUDA Significantly Improved OS Versus Placebo as Adjuvant Therapy for Certain Patients With RCC Following Nephrectomy November 7, 2023
Ph 3 RUBY trial of Jemperli + chemotherapy meets OS endpoint in patients with primary advanced or recurrent endometrial cancer November 7, 2023
Ph 3 CheckMate-67T Trial of SC Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced/Metastatic ccRCC October 25, 2023
New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study Released October 25, 2023
Interim PK/PD and Clinical Data for MRT-2359 in Ph 1/2 Trial for MYC-Driven Solid Tumors announced October 25, 2023
New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized 1L HCC Study presented October 16, 2023
Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of OS in Resectable Stage II, IIIA or IIIB NSCLC October 16, 2023
Updated PC14586 Ph 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation October 16, 2023
Interim Results from Ph 2 Trial of IT LSAM-PTX in Locally Advanced Pancreatic Cancer Patients Announced October 16, 2023
Interim Safety and Immune Response Data from Ph 1/2 Trial of PDS0301 + Docetaxel in Metastatic Prostate Cancer announced October 16, 2023
Positive Preliminary Data from Ph 1 Dose Escalation Portion of Ph 1/2 KB-0742 Study presented October 16, 2023
Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors announced October 16, 2023
Positive Interim Ph 2 ASPEN-06 Trial Results of Evorpacept in Advanced HER2+ve Gastric Cancer Reported October 11, 2023
KEYTRUDA® Met Primary Endpoint of DFS in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery October 11, 2023
Ph 3 MARIPOSA Study Meets Primary Endpoint of PFS for RYBREVANT (amivantamab-vmjw) + Lazertinib vs Osimertinib in EGFR-Mutated NSCLC October 3, 2023
